33,161 reports of this reaction
4.5% of all RITUXIMAB reports
#2 most reported adverse reaction
DRUG INEFFECTIVE is the #2 most commonly reported adverse reaction for RITUXIMAB, manufactured by Genentech, Inc.. There are 33,161 FDA adverse event reports linking RITUXIMAB to DRUG INEFFECTIVE. This represents approximately 4.5% of all 743,156 adverse event reports for this drug.
RITUXIMAB has an overall safety score of 85 out of 100. Patients taking RITUXIMAB who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among RITUXIMAB users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for RITUXIMAB:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 33,161 FDA reports for RITUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 4.5% of all adverse event reports for RITUXIMAB, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking RITUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.